Tempus AI’s (TEM) Buy Rating Reiterated at BTIG Research

Tempus AI (NASDAQ:TEM)‘s stock had its “buy” rating restated by equities researchers at BTIG Research in a research note issued on Monday, Benzinga reports. They currently have a $80.00 price objective on the stock. BTIG Research‘s target price indicates a potential upside of 18.33% from the company’s current price.

Other research analysts have also issued research reports about the stock. Wall Street Zen upgraded shares of Tempus AI from a “sell” rating to a “hold” rating in a research note on Saturday, July 25th. Raymond James Financial set a $80.00 price objective on shares of Tempus AI in a report on Wednesday, September 2nd. Cantor Fitzgerald assumed coverage on shares of Tempus AI in a report on Wednesday, September 2nd. They issued an “overweight” rating and a $80.00 price objective for the company. Piper Sandler raised shares of Tempus AI from a “neutral” rating to an “overweight” rating and boosted their price objective for the company from $56.00 to $76.00 in a report on Tuesday, September 1st. Finally, HC Wainwright boosted their price objective on shares of Tempus AI from $66.00 to $68.00 and gave the company a “buy” rating in a report on Monday. Eleven equities research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $72.47.

Tempus AI Stock Down 0.0%

Shares of TEM opened at $67.61 on Monday. Tempus AI has a 52 week low of $40.77 and a 52 week high of $93.38. The firm has a market cap of $12.20 billion, a P/E ratio of -46.95 and a beta of 3.54. The firm’s 50-day simple moving average is $69.24 and its 200 day simple moving average is $57.26. The company has a debt-to-equity ratio of 3.06, a quick ratio of 3.16 and a current ratio of 3.30.

Tempus AI (NASDAQ:TEM) last announced its quarterly earnings results on Thursday, July 30th. The company reported ($0.04) EPS for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.10. Tempus AI had a negative net margin of 17.77% and a negative return on equity of 50.28%. The business had revenue of $382.49 million for the quarter, compared to analyst estimates of $379.69 million. During the same quarter in the prior year, the business earned ($0.22) EPS. Tempus AI’s quarterly revenue was up 21.6% on a year-over-year basis. On average, analysts forecast that Tempus AI will post -1.43 earnings per share for the current year.

Insider Activity at Tempus AI

In other news, EVP Andrew Polovin sold 2,951 shares of the company’s stock in a transaction that occurred on Thursday, September 17th. The shares were sold at an average price of $75.00, for a total transaction of $221,325.00. Following the completion of the sale, the executive vice president owned 135,189 shares of the company’s stock, valued at approximately $10,139,175. This represents a 2.14% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Eric Lefkofsky sold 250,000 shares of the company’s stock in a transaction that occurred on Tuesday, September 22nd. The stock was sold at an average price of $77.47, for a total transaction of $19,367,500.00. Following the sale, the chief executive officer directly owned 100,000 shares of the company’s stock, valued at approximately $7,747,000. This trade represents a 71.43% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 1,280,965 shares of company stock worth $80,397,564 in the last 90 days. Corporate insiders own 24.26% of the company’s stock.

Hedge Funds Weigh In On Tempus AI

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Eagle Health Investments LP acquired a new position in Tempus AI in the 1st quarter valued at approximately $11,588,000. Aristotle Atlantic Partners LLC acquired a new position in Tempus AI in the 1st quarter valued at approximately $6,179,000. Headlands Technologies LLC acquired a new position in Tempus AI in the 2nd quarter valued at approximately $2,689,000. Odyssean LLC acquired a new position in Tempus AI in the 2nd quarter valued at approximately $897,000. Finally, Canal Insurance CO increased its position in Tempus AI by 100.0% in the 1st quarter. Canal Insurance CO now owns 40,000 shares of the company’s stock valued at $1,809,000 after acquiring an additional 20,000 shares during the period. Institutional investors own 24.22% of the company’s stock.

Tempus AI Company Profile

Tempus AI, Inc is a healthcare technology company that uses artificial intelligence and data analytics to support precision medicine. The company combines clinical, molecular and imaging data to help physicians make more informed treatment decisions and to help researchers and biopharmaceutical companies develop therapies.

Its offerings include genomic testing and analysis, such as tissue- and blood-based tests, as well as software tools designed to assist with clinical decision-making, patient matching for clinical trials and the management of healthcare data.